Bharat Biotech could be declared ineligible in Brazil, says Covid CPI deputy chair
RIO DE JANEIRO, BRAZIL – The deputy chair of the Brazilian Senate parliamentary inquiry committee (Covid’s CPI), Senator Randolfe Rodrigues (Speech-AP), said in an interview Wednesday (11) that the Indian company Bharat Biotech, maker of Covaxin vaccine, could be deemed ineligible in Brazil in the final opinion of the investigation.
The company refused to submit the full texts of the contracts to sell vaccines to the country, in which Precisa Medicamentos acted as an intermediary, he said.
“We have already requested a hearing at the Indian Embassy, asking for international cooperation. We began to wonder if this contract actually existed. It was important for them to contribute because this CPI can discredit Bharat Biotech in Brazil. The best thing would be for them to contribute to the ongoing investigation,” he said.
Next week, businessman Francisco Maximiano, owner of Precisa, and his partner at 6M Participações, also a businessman in the pharmaceutical sector, Danilo Berndt Trento, will be called as witnesses.
According to Senator Rodrigues’s forecast, Trento was to speak to the committee on Tuesday and Maximiano on Wednesday. The agenda is not yet finalized, and more testimony may be included.
The Covid CPI has already been advised that Maximiano has appealed again to the Supreme Court (STF), so as not to have to attend.
More: Brazil news in English, every day from The Rio Times.
This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error
Brazil runoff, Sunday, October 25: Brazil runoff: date, poll closing times and when results start. Latest: Brazil runoff polls, Flávio 51%, Lula 49%.